论文部分内容阅读
目的1.评估TrizivirTM(AZT+3TC+ABC,TZV)治疗中国HIV/AIDS患者的疗效和安全性;2.HIV/AIDS患者的依从性;3.考察中国社区内HIV/AIDS患者服用固定剂量三联片治疗的可行性。方法80例HIV/AIDS患者进入治疗组。是一项单中心、开放式、无对照的临床试验。患者接受36个月的治疗,在治疗1,2,3,4,5,6,9,12,18,24,30和36个月按时到门诊随访。结果57例(71.3%)患者完成36个月治疗随访,23例(28.7%)在治疗过程中因药物不良反应、机会性感染复发、依从性不好或治疗失败而退出。57例治疗36个月后,CD4+T淋巴细胞计数平均增加252/μL,93.0%的患者显示病毒载量<400拷贝/mL。在36个月的治疗期间,有4例患者出现耐药。结论TZV抗病毒效果显著,对于病毒载量>500000拷贝/mL的患者也有很好的效果,CD4+T淋巴细胞计数均显示明显增加。TZV不良反应较少,与其他药物的相互作用较少,服用方便,患者服药依从性好,对某些患者尤其有毒瘾者不失为一种可以选用的治疗方案。
Objectives 1. Assess the efficacy and safety of TrizivirTM (AZT + 3TC + ABC, TZV) in the treatment of HIV / AIDS in China; 2. Compliance with HIV / AIDS patients; 3. Investigate the use of fixed- Feasibility of film treatment. Methods Eighty HIV / AIDS patients entered the treatment group. Is a single-center, open, uncontrolled clinical trial. Patients received 36 months of treatment and were on-time to outpatient visits at treatment days 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 30 and 36 months. Results Fifty-seven patients (71.3%) were followed up for 36 months. Twenty-three patients (28.7%) were exited during the course of treatment due to adverse drug reactions, recurrent opportunistic infections, poor compliance or failed treatment. After 57 months of treatment, CD4 + T lymphocyte counts increased 252 / μL on average, and 93.0% of patients showed a viral load of <400 copies / mL. During the 36 months of treatment, 4 patients developed resistance. Conclusion The anti-virus effect of TZV is significant. It also has a good effect on patients with viral load> 500000 copies / mL, and the CD4 + T lymphocyte count shows a significant increase. TZV less adverse reactions, less interaction with other drugs, easy to take, the patient medication compliance is good, for some patients, especially those who are addicted drug may be an alternative treatment options.